



Atty. Docket No.: 8654/2002

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application Filed: Eberhard Amtmann et al.

Examiner: Cook, Rebecca

Serial No.: 09/784,618

Group Art Unit: 1614

Filed: February 15, 2001

Conf. No.: 2652

Entitled: "Medicament Containing Platinum  
Complex Compounds and the Use  
Thereof"

**CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8a**

I hereby certify that this correspondence (and any paper or fee referred to as being enclosed) is being deposited with the United States Post Office as First Class Mail on the date indicated below in an envelope addressed to Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450.

Elizabeth N. Spar

Name of Person Mailing Paper

*Elizabeth N. Spar*

Signature of Person Mailing Paper

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT  
UNDER 37 CFR §§ 1.56, 1.97 AND 1.98**

Dear Sir:

In accordance with the duty of disclosure under 37 CFR § 1.56, Applicant submits this Supplemental Information Disclosure Statement pursuant to 37 CFR §§ 1.97 and 1.98 in the above-identified application for consideration by the Patent Office. A listing of the cited documents is also enclosed, as well as, for the Examiner's convenience, copies of the documents in the list.

Applicants do not intend to represent that any of the documents submitted herein are material prior art to this invention or that the list represents an exhaustive search of documents related to this invention.

Applicants respectfully request that the documents submitted herein be considered and made of record in this application.

Pursuant to CFR § 1.97(c)(2), because this Statement is being submitted after the mailing of the Final Office Action on the merits, authorization to charge the requisite fee of \$180.00 to Deposit Account 16-0085, Ref. 8654/2002 can be found on the transmittal letter accompanying this submission. Pursuant to CFR § 1.97(e)(1) Applicants submit that each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement.

Respectfully submitted,

*Elizabeth N. Spar*

Name: Kathleen M. Williams

Registration No.: 34,380

Customer No.: 29933

Palmer & Dodge LLP

111 Huntington Avenue

Boston, MA 02199-7613

Tel: 617-239-0100

Date: 12/16/03



USPTO Form 1449 Patent and Trademark Office <b>INFORMATION DISCLOSURE STATEMENT</b>				Attorney Docket No.		Serial No.	
				8654/2002		09/784,618	
				Applicant(s): Eberhard Amtmann et al.			
				Filing Date: February 15, 2001		Group: 1614	
<b>U.S. PATENT DOCUMENTS</b>							
Examiner Initial		Patent No.	Date	Name	Class	Subclass	Filing Date (if appropriate)
<b>FOREIGN PATENT DOCUMENTS</b>							
Examiner Initial		Document No.	Publication Date	Country	Class	Subclass	Translation
							YES
<b>OTHER DOCUMENTS</b> (including Author, Title, Date, Pertinent Pages, etc.)							
	1.	Kharkyevitch, D. A., (1987), <i>The dependence of the pharmacotherapeutic effect on the properties of pharmaceuticals and on their application conditions</i> . Medicine (Moscow) pp. 47 - 48 [English Translation of original Russian article].					
<b>EXAMINER</b>					<b>DATE CONSIDERED</b>		
<small>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.</small>							
<small>**Copies of references not provided at the time of this submission.</small>							